05340nam 2200649Ia 450 991097420510332120251116221027.01-61761-864-0(CKB)2560000000067957(EBL)3017851(SSID)ssj0000411458(PQKBManifestationID)12144844(PQKBTitleCode)TC0000411458(PQKBWorkID)10355071(PQKB)10095879(MiAaPQ)EBC3017851(Au-PeEL)EBL3017851(CaPaEBR)ebr10654822(OCoLC)923653915(BIP)28728248(EXLCZ)99256000000006795720091215d2010 uy 0engurcn|||||||||txtccrAggressive breast cancer /Regina H. DeFrina, editor1st ed.New York Nova Science Publishersc20101 online resource (276 p.)Cancer etiology, diagnosis and treatments seriesDescription based upon print version of record.1-60876-881-3 Includes bibliographical references and index.""AGGRESSIVE BREAST CANCER ""; ""AGGRESSIVE BREAST CANCER ""; ""CONTENTS ""; ""PREFACE""; ""RESEARCH AND REVIEW ARTICLES""; ""THE HER2 ONCOGENE IN BREAST CANCER ""; ""ABSTRACT ""; ""INTRODUCTION ""; ""HER PROTEIN RECEPTORS: SIGNAL TRANSDUCTION AND ONCOGENESIS ""; ""Intracellular Signaling Pathways ""; ""HER-Induced Cell Cycle Progression and Survival Pathways ""; ""OVER EXPRESSION OF HER2 AND THE PROGNOSIS OF INVASIVE BREAST CANCER ""; ""HER2 as A Prognostic Factor: Node-Positive Versus Node-Negative Disease""; ""HER Status and Lymphoid Infiltration """"HER2 and Progression of Early Breast Cancer Lesions to Invasive Carcinomas""""Relationship Between HER2 and Estrogen Receptor Expression ""; ""HER2 ABNORMALITIES IN OTHER TYPES OF BREAST MALIGNANCIES ""; ""HER2 ABNORMALITIES IN OTHER TYPES OF BREAST MALIGNANCIES ""; ""Evaluating HER2 in Breast Tissue ""; ""HER2 TARGETED THERAPY IN BREAST CANCER ""; ""The Role of Trastuzumab in HER2 Overexpressing Breast Cancer ""; ""The Role of Pertuzumab in HER2 Overexpressing Breast Cancer ""; ""The Role of Trastuzumab-DM1 in HER2 Overexpressing Breast Cancer """"Inhibiting Several HER Receptors: The Role of Lapatinib in HER2 Overexpressing Breast Cancer """"Circulating Serum HER2 Levels ""; ""PROPOSED RESISTANCE TO ANTI-HER2 THERAPIES ""; ""Altered Receptor-Antibody Interaction ""; ""Increased Signaling from other Receptors of the HER Family ""; ""Increased Signaling from other Receptors Activating the MAPK and PI3K Pathways ""; ""Constitutive Activation of Downstream Effectors ""; ""HER2 OVEREXPRESSION AND CHEMOTHERAPY ""; ""Anthracyclines ""; ""Taxanes ""; ""HER2 OVEREXPRESSION AND HORMONAL THERAPY """"CNS DISEASE IN HER2 OVEREXPRESSED BREAST CANCER """"CNS Metastases in Adjuvant Trials of Trastuzumab ""; ""Prognosis of CNS Metastases in HER2 Overexpressing Breast Cancer""; ""CONCLUSION ""; ""REFERENCES""; ""MULTI-DRUG RESISTANCE AS A PROBLEM CHALLENGING BREAST CANCER CHEMOTHERAPY ""; ""ABSTRACT ""; ""INTRODUCTION""; ""1) Non-Cellular MDR Mechanisms ""; ""2) Cellular MDR Mechanisms: ""; ""1. Changes in the intracellular accumulation and distribution of the drug ""; ""1a. Alteration of drug influx ""; ""1b. Alteration of drug efflux ""; ""NORMAL TISSUE DISTRIBUTION""""PHYSIOLOGICAL FUNCTIONS OF P-GP """"PHARMACOLOGICAL FUNCTIONS OF P-GP ""; ""P-GP SUBSTRATES ""; ""2. Increase in Drug Detoxification ""; ""3. Alterations of Drug Targets ""; ""4. Increase in DNA Repair Mechanism ""; ""5. Changes in Key Genes Controlling Cell Proliferation ""; ""5a. Changes in genes responsible for cell cycle control ""; ""5b. Abrogation of apoptosis ""; ""6. Micro-Environmental Stress-Mediated Resistance of Solid Tumors ""; ""7. Cancer Cell Dormancy and Resistant Cancer Stem Cells ""; ""MODULATION OF MDR PHENOTYPE """"I. Circumvention of Drug Resistance Induced by P-Gp Pump Protein ""Breast cancer is the most common cause of cancer in women and the second most common cause of cancer death in women in the U.S. While the majority of new breast cancers are diagnosed as a result of an abnormality seen on a mammogram, a lump or change in consistency of the breast tissue can also be a warning sign of the disease. Heightened awareness of breast cancer risk in the past decades has led to an increase in the number of women undergoing mammography for screening, leading to detection of cancers in earlier stages and a resultant improvement in survival rates. Still, breast cancer is the most common cause of death in women between the ages of 45 and 55.This new book presents the latest research in the field.Cancer etiology, diagnosis, and treatments.BreastCancerBreastDiseasesBreastCancer.BreastDiseases.616.99/449616.99/449DeFrina Regina H1863202MiAaPQMiAaPQMiAaPQBOOK9910974205103321Aggressive breast cancer4469710UNINA